Kevin Kunzmann

The selective inhibitor was previously approved to treat plaque psoriasis and psoriatic arthritis.

The rare disease patient population is smaller and in need of immediate treatment. What's next after the SENSCIS trial results?

Previous trials have sought out fracture risk between the therapies over 1 year, and have also found few differences.

The TNF-inhibitor biosimilar was shown to fare similarly to the marketed therapy in a 52-week efficacy trial.

The therapy will carry a one-year treatment advisory and boxed warning on its label for cardiovascular risks.

An aging US population, plus minimal non-invasive alternative options, determine the rate and scope of work an orthopedic surgeon sees today.

The therapy has been approved for use along with the One-Press injector—a device designed to fit comfortably in the patient’s hand and hide the needle through administration.

The first liquid formulation of the common gout therapy is anticipated to improve instances of dosing adjustment for patients.

The JAK1 inhibitor will be considered as a marketed once-daily therapy for moderate to severe RA in the second half of this year.

An assay designed to track TNF counts in recently-treated RA patients found that early reduction of the protein could indicate future problems for the patient.

What are the most overlooked, difficult-to-treat symptoms within menopause?

After nearly a year of therapy, 84.5% of patients treated with guselkumab achieved at least 90% severity index improvement, compared to 70% of those treated with secukinumab.

Tolsura was approved for patients with blastomycosis, histoplasmosis, and aspergillosis—infections most commonly associated with immunocompromising diseases such as HIV/AIDS or chronic rheumatic disorders.

The ACTPen was approved on the basis of a pair of clinical trials presented at the 2018 American Society for Clinical Pharmacology & Therapeutics Annual Meeting.

The findings led the team to believe a focus on treatment strategy, rather than disease activity, is more indicative of aortic distensibility improvement.

The designation was based on data from 7 clinical trials over the past decade which assessed Xolair's efficacy and safety versus various food allergens such as peanut, milk, and egg.

Galafold differs from common enzyme replacement therapy in that it increases the activity of the body’s deficient enzyme.

The oral therapy was previously approved for use in children aged 6 years and older with CF and 2 copies of the F508del-CFTR mutation, the most common genetic form of the disease.

Researchers suggested that anti-oxidants such as Vitamin C and E could delay or even reduce the risk of AMD in patients with gout, as they have been proven to have a beneficial effect in patients with AMD.

The coflex Interlaminar Stabilization disposable instrument kit is a serviceable outpatient set of injection molded instruments provided in a pre-sterilized peel pack for the posterior lumbar motion preservation solution.

The orthopedic surgeron from Northwell Health discussed the expectations of physically active older patients undergoing care for joints and knees.

The Biologics License Application is for another biosimilar to AbbVie's best-selling Humira drug.

The trial is the first head-to-head clinical comparison in ankylosing spondylitis investigating the superiority of secukinumab for slowing spinal bone damage versus proposed biosimilar adalimumab.